First-line use of Pfizer’s Bosulif cleared in the US
Pfizer’s Bosulif has been approved in the US to treat patients with newly-diagnosed Ph+ chronic myelogenous leukemia.
Read More
Tag: BFOR
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
